Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: A comparative study to losartan

Drugs under Experimental and Clinical Research

Volumn 30, Issue 3, 2004, Pages 125-132

  Makris, T K ^a   Stavroulakis, G ^a   Papadopoulos, D P ^a   Krespi, P ^a   Hatzizacharias, A ^a   Zilidis, A ^a   Tsoukala, C ^a   Votteas, V E ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; EPROSARTAN; FIBRINOGEN; LOSARTAN; THROMBOMODULIN;

ADULT; AGE; ARTICLE; BLOOD CLOTTING; BODY MASS; COMPARATIVE STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; SEX RATIO; SYSTOLIC BLOOD PRESSURE;

ACRYLATES; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBRINOGEN; FIBRINOLYSIS; FOLLOW-UP STUDIES; HEMOSTASIS; HUMANS; HYPERTENSION; IMIDAZOLES; LIPOPROTEINS; LOSARTAN; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTOR, ANGIOTENSIN, TYPE 1; THIOPHENES; THROMBOMODULIN; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 4043094773     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med., 342, 145, 2000.
2. Fox K.M., European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, 362, 782, 2003.
3. Ridker P.M., Gaboury C.L., Conlin P.R., et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic, function. Circulation, 87, 1969, 1993.
4. Brown N.J., Gainer J.V., Stein C.M., Vaughan D.E. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension, 33, 1431, 1999.
5. Hamsten A., de Faire V., Walldius G., et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet, 2, 3, 1987.
6. Folsom A.R., Rosamond W.D., Shahar E., et al Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (AR/C) Study Investigators. Circulation, 100, 736, 1999.
7. Blann A.D., Seigneur M., Steiner M., Boisseau M.R., McCollum C.N. Circulating endothelial markers in peripheral vascular disease: Relationship to the location and extent of atherosclerotic disease. Eur. J. Clin. Invest., 27, 916, 1997.
8. Golino P., Ravera A., Ragni M., et al. Involvement of tissue factor pathway inhibitor in the coronary circulation of patients with acute coronary syndromes. Circulation, 108, 108, 2003.
9. Brown N.J., Agirbasli M.A., Williams G.H., Litchfield W.R., Vaughan D.E. Effect of activation and inhibition of renin-angiotensin system on plasma PAI-1. Hypertension, 33, 965, 1998.
10. Vaughan D.E., Rouleau J.L., Ricker P.M., et al., on behalf of the HEART Study Investigators. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation, 96, 442, 1997.
11. Li-Saw-Hee F.L., Beevers D.G., Lip G.Y. Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in essential hypertension: A pilot prospective randomised double-blind parallel group trial. Int. J. Cardiol., 78, 241, 2001.
12. Brown N.J., Kumar S., Painter C.A., Vaughan D.E. ACE inhibition versus angiotensin type 1 receptor antagonism: Differential effects on PAI-1 over time, Hypertension, 40, 859, 2002.
13. Erdem Y., Usalan C., Haznedaroglu I.C., et al. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am. J. Hypertens., 12, 1071, 1999.
14. Brown N.J., Agirbasli M.A., Vaughan D.E. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic, balance in humans. Hypertension, 34, 285, 1999.
15. Fogari R., Mugellini A., Zoppi A., et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am. J. Hypertens., 15, 316, 2002.
16. Makris T.K., Stavroulakis G.A., Krespi P.G., et al. Fibrinolytic/ hemostatic variables in arterial hypertension: Response to treatment with irbersartan or atenolol. Am. J. Hypertens., 13, 783, 2000.
17. The Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The fifth report of the JNC. Arch. Intern. Med., 153, 154, 1993.
18. Seidell J.C., Cigolini M., Deslypere J.P., et al. Body fat distribution in relation to physical activity and smoking habits in 38-year-old European men. The European Fat Distribution Study. Am. J. Epidemiol., 133, 257, 1991.
19. Lip G., Blann A., Jones A., Lip P., Beevers D. Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy Am. J. Cardiol., 80, 1566, 1997.
20. Makris T.K., Tsoukala C., Krespi P., et al. Haemostasis balance disorders in patients with essential hypertension. Thromb. Res., 88(2), 99, 1997.
21. Levy P.J., Yunis C., Owen J., et al. Inhibition of platelet aggregability by losartan in essential hypertension. Am. J. Cardiol., 86(11), 1188, 2000.
22. Fogari R., Zoppi A., Preti P., et al. Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women. Am. J. Hypertens., 14, 921, 2001.
23. Erlinger T.P., Conlin P.R., Macko R.F., et al. The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis. J. Hum. Hypertens., 16, 391, 2002.
24. Kerins D.M., Hao Q., Vaughan D.E. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J. Clin. Invest., 96, 2515, 1995.
25. Abrahamsen C.T., Barone F.C., Campell W.G. Jr., et al. The angiotensin II type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontantaneously hypertensive stroke-prone rats with accelerated hypertension. J. Pharmacol. Exp. Ther., 301, 21, 2002.
26. Wong V.Y., Laping N.J., Contino L.C., et al. Gene expression in rats with renal disease treated with the angiotensin II receptor antagonist, eprosartan. Physiol. Genomics, 4, 35, 2000.
27. Koh K.K., Ahn J.Y., Han S.H., et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J. Am. Coll. Cardiol., 42, 905, 2003.
28. 1 receptor in rat aortic and cardiac PAI-1 gene expression. Arterioscler. Thromb. Vasc. Biol., 20, 2297, 2000.
29. Lottermoser K., Weisser B., Hertfelder H.J., et al. Antihypertensive drug treatment and fibrinolytic function. Am. J. Hypertens., 11, 378, 1998.
30. 1 receptors. Br. J. Pharmacol., 126, 1057, 1999.
31. Puig J.G., Lopez M.A., Bueso T.S., et al. Clinical profile of eprosartan. Cardiovasc. Drugs Ther., 16, 543, 2002.
32. Guimaraes S., Paiva M.Q., Moura D. Different receptors for angiotensin II at pre- and postfunctional level of the canine mesenteric and pulmonary arteries. Br. J. Pharmacol., 124, 1207, 1998.
33. Brooks D.P., Ruffolo J.R. Pharmacological mechanism of angiotensin II receptor antagonists: Implications for the treatment of elevated systolic blood pressure. J. Hypertens., 17, S27, 1999.
34. Yamamoto K., Takeshita K., Shimokawa T., et al. Plasminogen activator inhibitor-1 is a major stress-regulated gene: Implications for stress-induced thrombosis in aged individuals. Proc. Natl. Acad. Sci. USA, 99, 890, 2002.
35. Von Kanel R., Dimsdale J.E. Effects of sympathetic activation by adrenergic infusions on hemostasis in vivo. Eur. J. Haematol., 65, 357, 2000.
36. Seigneur M., Dufourcq P., Conn C. Plasma thrombomodulin levels increase with the severity of the diabetic retinopathy. Blood Coagul. Fibrinolysis, 5, 845, 1994.
37. Leurs P.B., van Oerle R., Wolffenbuttel B.H., Hamulyak K. Increased tissue factor pathway inhibitor (TPPI) and coagulation in patients with insulin-dependent diabetes mellitus. Thromb. Haemost., 77, 472, 1997.
38. Nishimura H., Tsuji H., Masuda H., et al. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb. Haemost., 77, 1189, 1997.
39. Lorena M., Perolini S., Casazza F., Milani M., Cimminiello C. Fluvastatin and tissue factor pathway inhibitor in type IIA and IIB hyperlipidemia and in acute myocardial infarction. Thromb. Res., 87, 397, 1997.
40. Belz G.G., Man in't Veld A.J. Differences among angiotensin II receptor antagonists: Choosing the optimal agent in clinical practice. Eur. Heart J. Suppl., 2(Suppl. B), B8, 2000.
41. 1 receptors enhances baroreflex control of heart rate in conscious rabbits with heart failure. Am. J. Physiol., 271, R303, 1996.
42. Juhan-Vague I., Alessi M.C. PAI-1, obesity insulin resistance and risk of cardiovascular events. Thromb. Haemost., 78(Suppl. 1), 656, 1997.